Immunovaccine Inc. announced the signing of a research agreement with Oncothyreon Inc. to develop a potential therapeutic cancer vaccine. Under the agreement, Oncothyreon's ONT-10, a therapeutic vaccine product candidate, will be formulated in Immunovaccine's DepoVax delivery platform for preclinical testing.
Oncothyreon's ONT-10 is a synthetic MUC1-based liposomal glycolipopeptide cancer vaccine. Immunovaccine's DepoVax platform is a lipid in oil-depot vaccine delivery and enhancement technology. The goal of this collaboration is to evaluate the ability of this combined vaccine formulation to elicit strong and long lasting immune responses against a well known cancer-associated antigen.
"We are pleased to work with Immunovaccine to explore whether their DepoVax technology can further enhance the activity of our synthetic liposomal MUC1 vaccine in preclinical studies," said Dr. Scott Peterson, Oncothyreon's vice president of research and development.
"Oncothyreon is recognized for developing innovative oncology immunotherapeutics and we are delighted to be collaborating with them to demonstrate how our DepoVax technology can maximize the immune activation potential of their vaccine candidate," said Dr Marc Mansour, Immunovaccine's vice president of research and development.
Immunovaccine Inc. is a clinical stage vaccine development company focused on the commercialization of its patented DepoVax vaccine delivery technology and product candidates. The company continues to strengthen its vaccine pipeline through licensing and strategic partnerships to develop therapeutic cancer and infectious disease vaccines.